CLAIRITY BREAST is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk. By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
Dr. Connie Lehman
BOSTON–(BUSINESS WIRE)–Clairity, Inc., advancing AI-powered human health solutions, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston, with its CEO, Jeff Luber, presenting the company update.
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram.
Clairity, Inc. is proud to announce a $1M investment from the Breast Cancer Research Foundation (BCRF) in support of Clairity, a leading innovator in AI-powered tools for breast cancer risk assessment.
CLAIRITY BREAST is launching soon.
Be the first to know when it launches, and how you can get it.
